Loading
Triptorelin (Trelstar) is a one-, three- or six-monthly injection that switches off testosterone production for men with advanced prostate cancer.
Triptorelin pamoate was approved by the FDA in June 2000 (3.75 mg monthly), with 11.25 mg three-monthly (2001) and 22.5 mg six-monthly (2010) depots following, for palliative treatment of advanced prostate cancer; the pivotal randomised trial of 277 men showed castrate testosterone suppression comparable to leuprolide. As Decapeptyl it has been used in Europe since the 1980s for prostate cancer, endometriosis and, in premenopausal breast cancer, for ovarian function suppression in the SOFT and TEXT trials that established the combination with exemestane. Hot flushes, loss of bone density, metabolic effects and initial flare (covered with an antiandrogen) are shared with the class.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Synthetic decapeptide GnRH agonist; continuous stimulation desensitises pituitary GnRH receptors, suppressing LH and testosterone to castrate levels after an initial surge. Connects to Androgen receptor.
1.Triptorelin binds Androgen receptor.
| Region | Year | Indication |
|---|---|---|
| US | 2000 | Palliative treatment of advanced prostate cancer |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Triptorelin" OR ABSTRACT:"Triptorelin" OR TITLE:"Trelstar" OR ABSTRACT:"Trelstar" OR TITLE:"Decapeptyl" OR ABSTRACT:"Decapeptyl" OR TITLE:"Triptodur paediatric" OR ABSTRACT:"Triptodur paediatric") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Triptorelin, not a curated reading list.
Shares Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer, Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer, Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer, Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer.
Shares Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT, Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer, Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging, Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer.
Shares Verity Pharmaceuticals, Buserelin, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists.
Shares Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer, Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists.
Shares Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT, Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging, Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial, Androgen deprivation & AR pathway inhibitors.
Shares Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT, Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer, Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer, Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer.
Shares Buserelin, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists, Prostate cancer.
Shares Buserelin, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists, Prostate cancer.